Endorectal MR Imaging and MR Spectroscopic Imaging for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy: Preliminary Experience

PURPOSE: To evaluate endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging for the depiction of locally recurrent prostate cancer after external beam radiation therapy.

MATERIALS AND METHODS: Endorectal MR imaging and MR spectroscopic imaging were performed in 21 patients with biochemical failure after external beam radiation therapy for prostate cancer. Two readers independently and retrospectively reviewed MR images and rated the likelihood of recurrent tumor on a five-point scale. Spectroscopic voxels were considered suspicious for malignancy if the choline level was elevated and citrate was absent. Receiver operating characteristic curve analysis was used to assess cancer detection in each side of the prostate with endorectal MR imaging and spectroscopic imaging at different thresholds based on the scores assigned by the two readers and on the number of suspicious voxels in each hemiprostate, respectively. The presence or absence of cancer at subsequent transrectal biopsy was used as the standard of reference.

RESULTS: Biopsy demonstrated locally recurrent prostate cancer in nine hemiprostates in six patients. The area under the receiver operating characteristic curve for the detection of locally recurrent cancer with MR imaging was 0.49 and 0.51 for readers 1 and 2, respectively. By using the number of suspicious voxels to define different diagnostic thresholds, the area under the receiver operating characteristic curve for MR spectroscopic imaging was significantly (P < .005) higher, at 0.81. In particular, the presence of three or more suspicious voxels in a hemiprostate showed a sensitivity and specificity of 89% and 82%, respectively, for the diagnosis of local recurrence. Seven hemiprostates demonstrated complete metabolic atrophy at spectroscopic imaging and only postirradiation atrophy at biopsy.

CONCLUSION: Preliminary data suggest that MR spectroscopic imaging, but not endorectal MR imaging, may be of value for the depiction of locally recurrent prostate cancer after radiation therapy.

© RSNA, 2004

References

  • 1 American Cancer Society. Cancer facts and figures 2003 Atlanta, Ga: American Cancer Society, 2003; 10.
  • 2 Cooperberg MR, Koppie TM, Lubeck DP, et al. How potent is potent? evaluation of sexual function and bother in men who report potency after treatment for prostate cancer—data from CaPSURE. Urology 2003; 61:190-196.
  • 3 Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37:1035-1041.
  • 4 Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 1999; 86:1557- 1566.
  • 5 Letran JL, Brawer MK. Management of radiation failure for localized prostate cancer. Prostate Cancer Prostatic Dis 1998; 1:119-127.
  • 6 Carroll PR, Presti JC, Jr, Small E, Roach M, 3rd. Focal therapy for prostate cancer 1996: maximizing outcome. Urology 1997; 49(suppl 3A):84-94.
  • 7 Jhaveri FM, Klein EA. How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol 1999; 17:130-134.
  • 8 Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001; 219:432-439.
  • 9 Cher ML, Bianco FJ, Jr, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998; 160:1387-1391.
  • 10 Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M, 3rd. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 2001; 219:817-821.
  • 11 Chan TW, Kressel HY. Prostate and seminal vesicles after irradiation: MR appearance. J Magn Reson Imaging 1991; 1:503-511.
  • 12 Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology 1999; 213:473-480.
  • 13 Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213:481-488.
  • 14 Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223:91-97.
  • 15 Menard C, Smith IC, Somorjai RL, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 2001; 50:317-323.
  • 16 Nash PA, Bruce JE, Indudhara R, Shinohara K. Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 1996; 155:607-609.
  • 17 Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 1996; 198:795-805.
  • 18 Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997; 202:697-702.
  • 19 Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997; 38:311-321.
  • 20 Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002; 16:451-463.
  • 21 Kurhanewicz J, Vigneron DB, Hricak H, et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996; 200:489-496.
  • 22 Mueller-Lisse UG, Swanson MG, Vigneron DB, et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001; 46:49-57.
  • 23 Mueller-Lisse UG, Vigneron DB, Hricak H, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional H-1 MR spectroscopy and MR imaging—clinicopathologic case-controlled study. Radiology 2001; 221:380-390.
  • 24 Parivar F, Hricak H, Shinohara K, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996; 48:594-599.
  • 25 Parivar F, Kurhanewicz J. Detection of recurrent prostate cancer after cryosurgery. Curr Opin Urol 1998; 8:83-86.
  • 26 Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step-section histology. J Urol 2000; 164:400-404.
  • 27 Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999; 161:494-498.
  • 28 Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data Oxford, England: Clarendon, 1994; 146-167.
  • 29 Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174.
  • 30 Efron B, Tibshirani RJ. An introduction to the bootstrap San Francisco, Calif: Chapman & Hill, 1993.
  • 31 Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. I. Metabolic relationships. Prostate 1991; 18:25-46.
  • 32 Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. II. Hormonal relationships in normal and neoplastic prostate. Prostate 1991; 19:181-205.
  • 33 Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982; 6:541-551.
  • 34 Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? —results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48:355-367.
  • 35 Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995; 153:104-110.

Article History

Published in print: Nov 2004